The Bacterial Composition of the Stomach in Reflux Disease
NCT ID: NCT03835663
Last Updated: 2024-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
100 participants
OBSERVATIONAL
2018-06-04
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In GORD surgical therapy is the most successful preventing cancer but around 85% of patient experience complications afterwards. Acid suppressing medications are reducing the risk of oesophageal cancer but equally increasing the risk of gastric cancer. They also shorten patients' life expectancy and often fail to provide relief. Analysis of stool samples of patients with GORD demonstrated different gut bacterial compositions to normal and rather resembled the one found in cancer.
There is a clear need to improve the outcome of OG cancer. This could be achieved by identifying bacteria responsible for cancer development in gastric tissue, gastric content and saliva and potentially eliminate them hence avoid the development of cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Difference of Gastric Microbiota in the Process of Correa's Model.
NCT02833363
Fecal Helicobacter Pylori Gene Detection for Gastric Cancer
NCT06943781
OLGA and OLGIM Stage System for Gastric Cancer
NCT03380052
An Observational Study for Gastric Cancer in Asymptomatic Carriers of High Risk Helicobacter Pylori
NCT06896370
Atrophic Gastritis Predicts the Risk of Gastric Cancer
NCT06203327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with non erosive reflux
Patients with symptoms of reflux but no evidence of oesophagitis or Barretts oesophagus on endoscopy.
No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
Standard upper GI endoscopy with biopsies
Patients with erosive reflux
Patients with symptoms of reflux with evidence of oesophagitis or Barretts oesophagus on endoscopy.
No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
Standard upper GI endoscopy with biopsies
Patients with no reflux
Patients with healthy oesophago-gastric mucosa and no symptoms of reflux.
No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
Standard upper GI endoscopy with biopsies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
Standard upper GI endoscopy with biopsies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Imperial College Healthcare, St Mary's Hospital, Paddington
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R18055
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.